Literature DB >> 21614589

Lack of germline PALB2 mutations in melanoma-prone families with CDKN2A mutations and pancreatic cancer.

Xiaohong R Yang1, Lea Jessop, Timothy Myers, Laufey Amundadottir, Ruth M Pfeiffer, William Wheeler, Kristen M Pike, Jeff Yuenger, Laurie Burdett, Meredith Yeager, Stephen J Chanock, Margaret A Tucker, Alisa M Goldstein.   

Abstract

The presence of pancreatic cancer (PC) in melanoma-prone families has been consistently associated with an increased frequency of CDKN2A mutations, the major high-risk susceptibility gene identified for melanoma. However, the precise relationship between CDKN2A, melanoma and PC remains unknown. We evaluated a recently identified PC susceptibility gene PALB2 using both sequencing and tagging to determine whether PALB2 might explain part of the relationship between CDKN2A, melanoma, and PC. No disease-related mutations were identified from sequencing PALB2 in multiple pancreatic cancer patients or other mutation carrier relatives of PC patients from the eight melanoma-prone families with CDKN2A mutations and PC. In addition, no significant associations were observed between 11 PALB2 tagging SNPs and melanoma risk in 23 melanoma-prone families with CDKN2A mutations or the subset of 11 families with PC or PC-related CDKN2A mutations. The results suggested that PALB2 does not explain the relationship between CDKN2A, melanoma, and pancreatic cancer in these melanoma-prone families.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21614589      PMCID: PMC3244023          DOI: 10.1007/s10689-011-9447-9

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  15 in total

Review 1.  Genetics of melanoma predisposition.

Authors:  Nicholas K Hayward
Journal:  Oncogene       Date:  2003-05-19       Impact factor: 9.867

2.  Rank truncated product of P-values, with application to genomewide association scans.

Authors:  Frank Dudbridge; Bobby P C Koeleman
Journal:  Genet Epidemiol       Date:  2003-12       Impact factor: 2.135

3.  Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.

Authors:  Christopher S Carlson; Michael A Eberle; Mark J Rieder; Qian Yi; Leonid Kruglyak; Deborah A Nickerson
Journal:  Am J Hum Genet       Date:  2003-12-15       Impact factor: 11.025

4.  Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.

Authors:  Bing Xia; Qing Sheng; Koji Nakanishi; Akihiro Ohashi; Jianmin Wu; Nicole Christ; Xinggang Liu; Maria Jasin; Fergus J Couch; David M Livingston
Journal:  Mol Cell       Date:  2006-06-23       Impact factor: 17.970

5.  High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.

Authors:  Alisa M Goldstein; May Chan; Mark Harland; Elizabeth M Gillanders; Nicholas K Hayward; Marie-Francoise Avril; Esther Azizi; Giovanna Bianchi-Scarra; D Timothy Bishop; Brigitte Bressac-de Paillerets; William Bruno; Donato Calista; Lisa A Cannon Albright; Florence Demenais; David E Elder; Paola Ghiorzo; Nelleke A Gruis; Johan Hansson; David Hogg; Elizabeth A Holland; Peter A Kanetsky; Richard F Kefford; Maria Teresa Landi; Julie Lang; Sancy A Leachman; Rona M Mackie; Veronica Magnusson; Graham J Mann; Kristin Niendorf; Julia Newton Bishop; Jane M Palmer; Susana Puig; Joan A Puig-Butille; Femke A de Snoo; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Linda Whitaker; Emanuel Yakobson
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

6.  Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations.

Authors:  Alisa M Goldstein; Maria Teresa Landi; Shirley Tsang; Mary C Fraser; David J Munroe; Margaret A Tucker
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-09       Impact factor: 4.254

7.  Cancer risks in BRCA2 mutation carriers.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

8.  Germline PALB2 mutation analysis in breast-pancreas cancer families.

Authors:  Zsofia K Stadler; Erin Salo-Mullen; Nelly Sabbaghian; Jennifer A Simon; Liying Zhang; Sara H Olson; Robert Kurtz; Kenneth Offit; William D Foulkes; Mark E Robson; Marc Tischkowitz
Journal:  J Med Genet       Date:  2011-03-17       Impact factor: 6.318

9.  Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.

Authors:  A M Goldstein; J P Struewing; A Chidambaram; M C Fraser; M A Tucker
Journal:  J Natl Cancer Inst       Date:  2000-06-21       Impact factor: 13.506

10.  Familial melanoma, pancreatic cancer and germline CDKN2A mutations.

Authors:  Alisa M Goldstein
Journal:  Hum Mutat       Date:  2004-06       Impact factor: 4.878

View more
  5 in total

1.  Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.

Authors:  Robert C Grant; Iris Selander; Ashton A Connor; Shamini Selvarajah; Ayelet Borgida; Laurent Briollais; Gloria M Petersen; Jordan Lerner-Ellis; Spring Holter; Steven Gallinger
Journal:  Gastroenterology       Date:  2014-12-02       Impact factor: 22.682

2.  Appearance of malignant melanoma after a non-cutaneous cancer diagnosis.

Authors:  Ugo Bottoni; Rita Clerico; Giovanni Paolino; Marina Ambrifi; Cecilia Luci; Paola Corsetti; Stefano Calvieri
Journal:  Ecancermedicalscience       Date:  2013-05-07

3.  Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.

Authors:  Thomas P Potjer; Nienke van der Stoep; Jeanine J Houwing-Duistermaat; Ingrid C A W Konings; Cora M Aalfs; Peter C van den Akker; Margreet G Ausems; Charlotte J Dommering; Lizet E van der Kolk; Merel C Maiburg; Liesbeth Spruijt; Anja Wagner; Hans F A Vasen; Frederik J Hes
Journal:  BMC Res Notes       Date:  2015-06-26

4.  Assessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutation carriers.

Authors:  E Christodoulou; M Visser; T P Potjer; N van der Stoep; M Rodríguez-Girondo; R van Doorn; N Gruis
Journal:  Fam Cancer       Date:  2019-10       Impact factor: 2.375

5.  Assessment of PALB2 as a candidate melanoma susceptibility gene.

Authors:  Lauren G Aoude; Mai Xu; Zhen Zhen Zhao; Michael Kovacs; Jane M Palmer; Peter Johansson; Judith Symmons; Jeffrey M Trent; Nicholas G Martin; Grant W Montgomery; Kevin M Brown; Nicholas K Hayward
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.